A detailed history of Yousif Capital Management, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Yousif Capital Management, LLC holds 7,097 shares of LGND stock, worth $791,741. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,097
Previous 6,781 4.66%
Holding current value
$791,741
Previous $571,000 24.34%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$82.7 - $110.11 $26,133 - $34,794
316 Added 4.66%
7,097 $710,000
Q2 2024

Jul 31, 2024

SELL
$68.53 - $87.91 $45,572 - $58,460
-665 Reduced 8.93%
6,781 $571,000
Q1 2024

Apr 26, 2024

SELL
$68.64 - $89.2 $51,136 - $66,454
-745 Reduced 9.1%
7,446 $544,000
Q4 2023

Feb 01, 2024

BUY
$49.57 - $72.63 $2,478 - $3,631
50 Added 0.61%
8,191 $585,000
Q3 2023

Oct 30, 2023

SELL
$58.86 - $72.67 $33,550 - $41,421
-570 Reduced 6.54%
8,141 $487,000
Q2 2023

Aug 02, 2023

SELL
$69.53 - $79.33 $24,822 - $28,320
-357 Reduced 3.94%
8,711 $628,000
Q1 2023

May 02, 2023

SELL
$65.67 - $77.08 $81,759 - $95,964
-1,245 Reduced 12.07%
9,068 $667,000
Q4 2022

Jan 09, 2023

SELL
$61.72 - $96.74 $207,379 - $325,046
-3,360 Reduced 24.57%
10,313 $0
Q3 2022

Nov 04, 2022

SELL
$0.01 - $107.56 $8 - $87,768
-816 Reduced 5.63%
13,673 $1.18 Million
Q2 2022

Aug 01, 2022

SELL
$74.52 - $117.06 $100,229 - $157,445
-1,345 Reduced 8.49%
14,489 $1.29 Million
Q1 2022

May 12, 2022

BUY
$94.99 - $151.56 $21,372 - $34,101
225 Added 1.44%
15,834 $1.78 Million
Q4 2021

Jan 31, 2022

BUY
$127.69 - $165.85 $1.99 Million - $2.59 Million
15,609 New
15,609 $2.41 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.88B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Yousif Capital Management, LLC Portfolio

Follow Yousif Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yousif Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Yousif Capital Management, LLC with notifications on news.